Pharm-Olam Blog

New Name and Branding Reflect Company’s Mission to Help Bring Next-Generation Therapies to Light News Summary Rebranding comes after a series of strategic acquisitions, most recently Pharm-Olam Company’s newly combined services address clinical development and consulting needs of small and mid-sized biotechs New name unites worldwide experienced workforce in its singular mission  

Newly Combined Company Uniquely Positioned to Serve Small and Mid-Sized Biopharmaceutical Companies

HOUSTON, Texas, May 10, 2021 – Pharm-Olam, a global, midsized CRO offering full-service clinical development solutions for infectious diseases, vaccines, rare and orphan diseases along with oncology, is now enrolling volunteers in the United Kingdom into a pivotal Phase III COVID-19 vaccine study. Visit ukcovid19study.com for more information about participation. The Phase III “Cov-Compare” trial (VLA2001-301) will compare Valneva’s SARS-CoV-2 vaccine candidate, VLA2001, against AstraZeneca’s conditionally approved vaccine, Vaxzevria [1], in a comparative immunogenicity trial. There will be roughly 4,000 people participating in this study. Pharm-Olam is the full-service provider for this study, utilizing leading technology platforms.

HOUSTON, Texas, January 4, 2021 – Pharm-Olam, a global mid-sized clinical research organization (CRO), has been selected by the U.S. Department of Defense’s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to lead and provide full service clinical trial support of the Adalimumab COVID Therapeutic Trial. The JPEO-CBRND awarded Pharm-Olam a $36.3 million agreement to execute an adaptive, outpatient Phase II/III clinical trial of the monoclonal antibody, where adalimumab will be tested as a treatment against the inflammatory response and associated complications brought on by COVID-19.

HOUSTON, Texas, October 8, 2020 – Pharm-Olam, a global mid-sized clinical research organization (CRO), has been selected by the Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response, to join their Clinical Studies Network. Under the terms of the contract, Pharm-Olam will provide routine and/or response clinical services for the advanced development of medical countermeasures (MCMs).

HOUSTON, Texas, September 23, 2020 – Pharm-Olam, a global mid-sized clinical research organization (CRO), has been selected by the U.S. Department of Defense (DOD) to build capability at military treatment facilities in order to support Phase III clinical trials of one or more lead COVID-19 vaccine candidates being developed under Operation Warp Speed. The CRO will provide project management, contract management, and clinical trial site support to participating military treatment facility investigative sites. Pharm-Olam will be partnering with The Geneva Foundation (Geneva), which is dedicated to serving military medical researchers with the on-site support needed to operationalize clinical trials.

Houston, June 24, 2020 – Pharm-Olam, a global midsized clinical research organization (CRO), today announced that they completed a change of ownership transaction on Friday June 19, 2020. This transaction provides Pharm-Olam with enhanced financial flexibility and access to additional capital to support its growth strategy, as it continues to enhance their services in the company’s five core therapeutic areas: oncology-hematology, infectious disease and vaccines, autoimmune, allergy and rare disease.

Houston, June 16th, 2020 – Pharm-Olam, LLC, a global, midsized CRO offering full-service clinical development solutions to the pharmaceutical and biotech industry, is launching Protocol Optimization Services to support the study development needs of their biopharma clients. The Protocol Optimization Service will benchmark a sponsor’s study design against other similar clinical trials and identify optimization opportunities for consideration and inclusion. This service will aid the development of lean and cost-effective study design while also maximizing study value through balancing patient and site burden with the achievement of planned primary and secondary study endpoints.